EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group clinical trials

Yasuhiko Matsumori, Miki Ishida, Katsuhiro Iba, Byung-Kun Kim, Xiaoping Ning, Masami Nakai iD, Nobuyuki Koga

Headache: The Journal of Head and Face Pain · 2023

DOI: 10.1111/head.14606 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2023. Verfasst von Yasuhiko Matsumori und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sendai Headache and Neurology Clinic, Sendai, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Migraine Disorders, Outcome Assessment, Health Care, Quality of Life. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate quality of life (QoL) endpoints from two 12‐week trials investigating fremanezumab efficacy and safety in Japanese/Korean patients with chronic (CM) or episodic (EM) migraine.

Background

Migraine is a leading cause of disability and affects QoL considerably, interfering with work and daily activities, social and family life, and emotional wellbeing.

Methods

This planned exploratory analysis used data from two multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group studies in which Migraine‐Specific QoL (MSQoL; Role Function‐Restrictive [RR], Role Function‐Preventive [RP], and Emotional Function [EF] domains) scores and Patient Global Impression of Change (PGIC) scores were pre‐specified QoL outcomes in individuals receiving monthly or quarterly fremanezumab or placebo. In both trials, MSQoL was assessed at baseline, and MSQoL and PGIC at Weeks 4, 8, and 12. PGIC responders had a score of ≥5 points, indicating significant improvement.

Results

Mean baseline MSQoL scores were similar across groups in both CM ( N = 565; RR, 60.3–61.5; RP, 78.5–80.0; EF, 69.0–71.4) and EM ( N = 353; RR, 68.6–71.1; RP, 83.1–85.7; EF, 76.7–81.9) trials. In the CM trial, all three MSQoL domains improved in both fremanezumab groups at 12 weeks compared with placebo: least squares mean (LSM) and standard error (SE) change from baseline, p versus placebo (quarterly; monthly; placebo): RR 14.9 (1.3), p = 0.030; 15.1 (1.4), p = 0.020; 11.6 (1.3); RP 8.9 (1.1), p = 0.007; 8.6 (1.1), p = 0.013; 5.4 (1.1); EF 13.3 (1.5), p < 0.001; 12.5 (1.5), p = 0.003; 7.5 (1.5). In the EM trial, RR/EF domains improved in both fremanezumab groups compared with placebo: LSM change from baseline, p versus placebo (quarterly; monthly; placebo): RR 16.3 (1.4), p = 0.003; 16.4 (1.3), p = 0.002; 11.6 (1.4); EF 13.0 (1.3), p < 0.001; 11.5 (1.2), p = 0.004; 7.4 (1.3); RP improved in the quarterly group RP 8.6 (1.1), p = 0.010; 7.6 (1.1), p = 0.066; 5.4 (1.1). The proportion of PGIC responders at Week 12 was greater in the monthly and quarterly fremanezumab groups compared with the placebo group in the CM (96/182 [52.7%] and 98/180 [54.4%] vs. 68/179 [38.0%]; p < 0.05) and EM trial (81/118 [68.6%] and 86/113 [76.1%] vs. 38/111 [34.2%]; p < 0.001).

Conclusion

Patients with EM/CM receiving monthly or quarterly fremanezumab, for a duration of 12 weeks, showed significant improvements in their QoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalMigraine DisordersOutcome Assessment, Health CareQuality of LifeAdultFemaleHumansMaleMiddle AgedYoung AdultChronic DiseaseDouble-Blind MethodJapanRepublic of KoreaTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

JapaneseKoreanchronic migraineepisodic migrainefremanezumabquality of life

Substanzen

Antibodies, Monoclonalfremanezumab

Autor:innen und Institutionen

  • Sendai Headache and Neurology Clinic, Sendai, Japan.
  • Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.
  • Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Republic of Korea.
  • Teva Branded Pharmaceutical Products R&D, Inc., West Chester, Pennsylvania, USA.
  • Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.
  • Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.

ORCID-Profile: Masami Nakai

Förderung

  • Otsuka Pharmaceutical Co., Ltd.
  • Otsuka Pharmaceutical

Zitieren

APA

Matsumori, Y., Ishida, M., Iba, K., Kim, B. K., Ning, X., Nakai, M., & Koga, N. (2023). Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group clinical trials. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14606

Vancouver

Matsumori Y, Ishida M, Iba K, Kim BK, Ning X, Nakai M, et al. Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group clinical trials. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14606

BibTeX
@article{Matsumori2023,
  author = {Matsumori, Yasuhiko and Ishida, Miki and Iba, Katsuhiro and Kim, Byung-Kun and Ning, Xiaoping and Nakai, Masami and Koga, Nobuyuki},
  title = {Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group clinical trials},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  doi = {10.1111/head.14606}
}
Kostenlos starten →